within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AB02_Imiglucerase;

model Imiglucerase
  extends Pharmacolibrary.Drugs.ATC.A.A16AB02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A16AB02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Imiglucerase is a recombinant enzyme replacement therapy used for the treatment of Gaucher disease type 1, a rare genetic lysosomal storage disorder. It is a modified form of the human enzyme β-glucocerebrosidase, and it helps reduce the accumulation of glucocerebroside in macrophages. Imiglucerase is approved and widely used as a standard care for Gaucher disease type 1.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with type 1 Gaucher disease following intravenous infusion. Data represent average PK values from published studies.</p><h4>References</h4><ol><li><p>Berger, J, et al., &amp; Berger, MG (2019). Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1. <i>Clinical pharmacokinetics</i> 58(4) 469–482. DOI:<a href=&quot;https://doi.org/10.1007/s40262-018-0708-8&quot;>10.1007/s40262-018-0708-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30128966/&quot;>https://pubmed.ncbi.nlm.nih.gov/30128966</a></p></li><li><p>Weinreb, NJ (2008). Imiglucerase and its use for the treatment of Gaucher&#x27;s disease. <i>Expert opinion on pharmacotherapy</i> 9(11) 1987–2000. DOI:<a href=&quot;https://doi.org/10.1517/14656566.9.11.1987&quot;>10.1517/14656566.9.11.1987</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18627336/&quot;>https://pubmed.ncbi.nlm.nih.gov/18627336</a></p></li><li><p>Sekijima, Y, et al., &amp; Fukushima, Y (2010). Successful pregnancy and lactation outcome in a patient with Gaucher disease receiving enzyme replacement therapy, and the subsequent distribution and excretion of imiglucerase in human breast milk. <i>Clinical therapeutics</i> 32(12) 2048–2052. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2010.11.008&quot;>10.1016/j.clinthera.2010.11.008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21118740/&quot;>https://pubmed.ncbi.nlm.nih.gov/21118740</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Imiglucerase;
